Posted by Michael Wonder on 11 Nov 2024
PHARMAC funds new medicine and removes renewal criteria for ADHD and narcolepsy treatments
11 November 2024 - PHARMAC will make two changes for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy this December – the funding of a new medicine, and the removal of renewal criteria for funded treatments.
“We’ve decided to fund lisdexamphetamine, a new stimulant medicine that will provide an additional treatment option for people with ADHD, and we’re also simplifying the renewal process,” says PHARMAC’s Chief Medical Officer, Dr David Hughes.
